Effect of estrogen on outcome in two randomized phase III studies of paclitaxel poliglumex (PPX) in advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
O'Byrne, K.
Singer, J. W.
Oldham, F. B.
Ross, H.
机构：
[1] St James Hosp, Dublin 8, Ireland
[2] Cell Therapeut, Seattle, WA USA
[3] Earle A Chiles Res Inst, Portland, OR USA
来源：
EJC SUPPLEMENTS | 2006年 / 4卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(06)70650-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
645
引用
收藏
页码：194 / 195
页数：2
相关论文
共 50 条
  • [1] Symptom relief in patients with non-small cell lung cancer (NSCLC) after treatment with paclitaxel poliglumex (PPX, XYOTAXTM):: phase III trial results
    Thatcher, N.
    EJC SUPPLEMENTS, 2005, 3 (02): : 325 - 325
  • [2] Paclitaxel/gemcitabine versus paclitaxel/vinorelbine in advanced non-small cell lung cancer (NSCLC): A phase III randomized study
    Kosmidis, P. A.
    Timotheadou, E.
    Koutras, A.
    Pentheroudakis, G.
    Christodoulou, C.
    Dimopoulos, A. M.
    Bafaloukos, D.
    Samantas, E.
    Pectasides, D.
    Syrigos, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] Paclitaxel poliglumex (PPX)/carboplatin vs paclitaxel/carboplatin for the treatment of PS2 patients with chemotherapy-naive advanced non-small cell lung cancer (NSCLC): A phase III study.
    Langer, CJ
    Socinski, MA
    Ross, H
    O'Byrne, KJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 1095S - 1095S
  • [4] Effect of gender on outcome in two randomized phase III trials of paclitaxel poliglumex (PPX) in chemonaive pts with advanced NSCLC and poor performance status (PS2).
    Ross, H.
    Bonomi, P.
    Langer, C.
    O'Brien, M.
    O'Byrne, K.
    Paz-Ares, L.
    Sandler, A.
    Socinski, M.
    Oldham, F.
    Singer, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 373S - 373S
  • [5] Paclitaxel poliglumex (PPx, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer
    Bonomi, Philip
    EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (04) : 415 - 422
  • [6] Paclitaxel poliglumex (PPX) in combination with carboplatin (carb) for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): Preliminary data.
    Nemunaitis, JJ
    Leighl, N
    Miller, W
    Cormier, Y
    Bernareggi, A
    Oldham, F
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 677S - 677S
  • [7] Dose-ranging study of the combination of paclitaxel poliglumex and pemetrexed in advanced non-small cell lung cancer (NSCLC)
    Slagle, B. M.
    Rigas, J. R.
    Dragnev, K. H.
    Williams, I.
    DiSalvo, W.
    Engman, C.
    Lipe, B.
    Simeone, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] Dose-ranging study of the combination of paclitaxel poliglumex and pemetrexed in advanced non-small cell lung cancer (NSCLC)
    Slagle, Brendan M.
    Rigas, James R.
    Dragnev, Konstantin H.
    DiSalvo, Wendye
    Williams, Ian
    Simeone, Sara
    Engman, Cocav
    Lipe, Brea
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S709 - S709
  • [9] Phase II study of oxaliplatin and paclitaxel in advanced non-small cell lung cancer (NSCLC).
    Mauer, AM
    Otterson, G
    Rudin, CM
    Villalona, M
    Ansari, RH
    Szeto, L
    Vokes, EE
    CLINICAL CANCER RESEARCH, 2000, 6 : 4576S - 4576S
  • [10] Phase II study of paclitaxel and gemcitabine in advanced non-small cell lung cancer (NSCLC).
    Lazaro, M
    Jorge, M
    Castellanos, J
    ANNALS OF ONCOLOGY, 2000, 11 : 109 - 109
12345